Raw pet food pulled after cats die with bird flu. Check these lots before feeding your pet
The Oregon Department of Agriculture urged pet owners to check the lot numbers on Wild Coast Raw pet food they have at home and stop feeding the product to their animals if they match certain lots after two cats were euthanized after eating it.
The cats became severely ill with bird flu, authorities said, after they ate the same brand of raw pet food, the latest in a string of pet deaths linked to the virus.
Testing confirmed the presence of the highly pathogenic avian influenza in both cats, which lived in separate households, and samples of the raw food, the department said in a statement.
The Washington State Department of Agriculture has also issued a public health notice warning consumers about the risk of some of Wild Coast Raw's products, which are produced in Olympia, Wa. Oregon health officials urged pet owners not to feed their animals undercooked or raw meat or raw (unpasteurized) milk, which is believed to have previously sickened and killed barn cats.
Tyler Duncan, founder of Wild Coast Pet Foods, said in a statement that the company is halting sales of lot #22660 and #22664 of their Chicken Feline Formula with a best buy date of 12/2025.
He said customers should dispose of the product and request a full refund from the place they purchased it. "If you currently feed our chicken formula and are concerned, I recommend cooking until 165 degrees, replacing with a non-poultry formula or replacing with a gently cooked formula," Duncan said.
Duncan said Wild Coast mainly sources its chicken meat from California and only buys human-grade poultry manufactured in facilities inspected by the U.S. Department of Agriculture. The company is working with a third-party lab for internal screening for bird flu in its food.
Raw food for pets is all the rage. Is the fad worth the risk of bird flu, salmonella?
California Gov. Gavin Newsom has declared a state of emergency over the bird flu outbreak which has wiped out millions of the state's chickens and turkeys in recent months and infected about two-thirds of the state's dairy herds since the end of August.
Last month, Los Angeles County health officials warned residents about another brand of pet food, Monarch Raw Pet Food, sold at farmers markets in California after the H5 bird flu virus was detected in product samples and was believed to have sickened five cats. That warning came a week after another brand, Northwest Naturals, recalled a line of raw and frozen chow linked to the death of another cat in Oregon that contracted bird flu.
U.S. Food and Drug Administration studies dating back to 2012 have found that raw pet foods are far more likely to carry disease. Despite pet deaths, recalls and health authority warnings, raw pet food has grown into a $3 billion industry in the U.S.
Domestic cats have been known to carry bird flu since 2004.
But the death rates seen in the current U.S. outbreak seem dramatically higher than what's been seen around the world, Kristen Coleman, an assistant professor at the University of Maryland School of Public Health, previously told USA TODAY. Before, about half of cats died, but now about 90% seem to be dying, said Coleman, who has been tracking those deaths.
Contributing: Eduardo Cuevas, Michael Loria and Amaris Encinas, USA TODAY; Reuters
This article originally appeared on USA TODAY: Company stops selling some raw pet foods after cats die with bird flu
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
2 days ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Yahoo
5 days ago
- Yahoo
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ('Dogwood' or the 'Company'), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025. Presentation Date: Wednesday, June 11, 2025 Time: 9:15am Easter Time (Track 1) Webcast Link: Mr. Duncan will be available for one-on-one meetings. To request a meeting and to register for the conference, click here: About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ('CINP'). Interim data from the ongoing Halneuron® Phase 2 CINP study are expected in Q4 of 2025. Dogwood's antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia ('FM') and Long-COVID ('LC'). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research. For more information, please visit Forward-Looking Statements: Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' "will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Investor Relations: CORE IR(516) 222-2560IR@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
31-05-2025
- Yahoo
Volunteer beekeepers swarm to rescue spilled hives after crash
A semi-truck carrying 250 million bees and their hives overturned on a Washington state roadway on Friday, unleashing an ominous cloud of unhappily buzzing insects. But more than two dozen volunteer beekeepers from the region of Whatcom County, snuggled along the U.S.-Canada border, may have saved the day, the Whatcom County Sheriff's Office said. They helped restore hives that had become dislodged in the crash, it said. "Hive boxes from the overturned truck were recovered, restored and returned to use," the sheriff's office said in an update Friday afternoon. "By morning, most bees should have returned to their hives and those responsible for their delivery will be in charge." The workday started with more uncertainty than optimism, as the crash shut down a roadway and inspired the sheriff's office to warn residents it could take a few days to corral the escapees. "The plan is to allow the bees to re-hive and find their queen bee," the office said in an earlier statement. "That should occur within the next 24-48 hours. The goal is to save as many of the bees as possible." Katie Buckley, the pollinator health coordinator for the Washington State Department of Agriculture, indicated many of the bees will not only survive but reconnect with their hives and travel on to their destination. "Bees are actually surprisingly sturdy," she told NBC affiliate KING of Seattle. People should still avoid the bees, and the area of the overturned semi-truck, because they're probably unhappy about being ejected, even if separation from their hives is temporary. "They're also probably having a bad day," she said. The sheriff's office, meanwhile, said the roadway could reopen Saturday morning, when the insects' owners will most likely take over, according to a statement. KING said it was working to determine where the bees were headed. The sheriff's office didn't say. The cause of the crash was not available. The sheriff's office thanked "the wonderful community of beekeepers," saying that its members "showed up to help ensure the rescue of millions of pollinating honey bees would be as successful as possible." This article was originally published on
